Objective: To identify immune-response signatures in the blood of multiple sclerosis (MS) patients predictive for clinical disease trajectories and supporting personalized treatment decisions based on pathobiological principles. Background: MS is a neuro-immunological disease representing with a broad spectrum of clinical manifestations and disease progression. To date it is still controversially discussed, whether discrete immune-response signatures in the blood represent inflammatory disease characteristics versus signs of early neurodegeneration with prognostic and therapeutic consequences. Design/Methods: In this multicentric prospective study, we employed high-dimensional flow cytometry and targeted proteomics to a discovery cohort of 378 treatment-naïve early (£ 2years from disease onset) MS patients from the NationMS cohort with comprehensive clinical and paraclinical data. Resulting data were analyzed applying state-of-the-art computational biology. Results were reproduced in a validation cohort of 78 MS patients. Results: We identified MS as a disease of disturbed immune-regulatory networks that can be detected in the blood. Early MS consists of four immunological endophenotypes associated with different HLA-backgrounds suggestive for discrete immunological pathways in disease pathogenesis. Immunological endophenotypes were mirrored by specific clinical and paraclinical disease trajectories exhibiting inflammatory disease characteristics versus signs of early neurodegeneration. Distinct immune-therapeutic principles differed in their capacity to normalize immune-response signatures associated with each endophenotype, exemplified by the limited effect of interferon-beta on immune-response signatures in patients with the inflammatory endophenotype, which was accompanied by increased clinical and imaging features of diseases progression in these patients. Conclusions: Ascertaining immune-response signatures in the blood of MS patients is an innovative clinical tool for predicting longitudinal outcomes and guiding personalized treatment decisions based on pathobiological principles. Disclosure: The institution of Catharina Groß has received research support from Biogen. The institution of Catharina Groß has received research support from Roche. Andreas Schulte-Mecklenbeck has nothing to disclose. Mrs. Steinberg has nothing to disclose. Timo Wirth has nothing to disclose. Dr. Lauks has nothing to disclose. Sergio Baranzini has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck Serono. Sergio Baranzini has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Sergio Baranzini has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Aventis. Sergio Baranzini has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nexilico. Sergio Baranzini has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono . Sergio Baranzini has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD SErono. Sergio Baranzini has stock in MATE Bioservices. The institution of Sergio Baranzini has received research support from Valhalla Charitable Fund. The institution of Sergio Baranzini has received research support from Genentech Inc. The institution of Sergio Baranzini has received research support from Salah Foundation. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Biogen Idec. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Merck Healthcare. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Novartis. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Roche. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Sanofi. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Bristol-Meyer-Squibbs. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Teva. Judith Bellmann-Strobl, MD has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Judith Bellmann-Strobl, MD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Judith Bellmann-Strobl, MD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Judith Bellmann-Strobl, MD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. The institution of Judith Bellmann-Strobl, MD has received research support from Bayer. The institution of Judith Bellmann-Strobl, MD has received research support from NEMOS. Dr. Buenger has nothing to disclose. Dr. Eilers has nothing to disclose. Maria Eveslage has nothing to disclose. Dr. Fleischer has nothing to disclose. Dr. Gisevius has nothing to disclose. Sergiu Groppa has nothing to disclose. Juergen Haas has nothing to disclose. Prof. Kerschensteiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Prof. Kerschensteiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Aventis. Prof. Kerschensteiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety...